U.S. Markets open in 1 hr 22 mins

Opiant Pharmaceuticals, Inc. (OPNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.73+0.03 (+0.23%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.70
Open10.56
Bid10.05 x 1000
Ask0.00 x 1400
Day's Range10.56 - 10.91
52 Week Range6.79 - 14.98
Volume7,218
Avg. Volume44,220
Market Cap46.028M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-0.44
Earnings DateMar 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.33
  • Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone
    GlobeNewswire

    Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone

    Pharmacodynamic study will compare OPNT003, nasal nalmefene, with nasal naloxone in reversing the respiratory depression produced by the synthetic opioid, remifentanilTop-line data expected in the fourth quarter This trial starts at a time when deaths resulting from opioid overdose are at record highs SANTA MONICA, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that the first subjects were dosed in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist OPNT003, nasal nalmefene, with nasal naloxone. The single-center, randomized, open-label study in heathy volunteers will evaluate the effectiveness of 3mg nasal nalmefene, in comparison to 4 mg nasal naloxone, to reverse the respiratory depression produced by the synthetic opioid, remifentanil. Details of this clinical trial can be found listed on www.clinicaltrials.gov. Identifier: NCT04828005. An overdose can be fatal when an opioid interrupts the body’s natural drive to breathe. Top-line data from the trial are expected in the fourth quarter 2021. According to provisional data from the Centers for Disease Control and Prevention (CDC), more than 63,000 opioid overdose deaths were recorded in the United States during the 12 months ending August 2020 – a 31% increase to the prior year and record high¹. The most common are overdoses from synthetic opioids, such as illicitly manufactured fentanyl, which is 50x more potent than heroin. “The initiation of this head-to-head study is an important step in our comprehensive development program for OPNT003, nasal nalmefene,” said Dr. Roger Crystal, President and CEO, Opiant Pharmaceuticals. “The potential for a faster acting, longer duration antagonist holds promise in the fight against an increasing number of opioid overdoses that have been driven by more powerful synthetic opioids, such as fentanyl. By directly comparing OPNT003 to nasal naloxone, we hope to generate additional data to support the potential therapeutic benefits of OPNT003, nasal nalmefene.” Multiple studies have demonstrated nalmefene’s potency to be more than five-fold higher than naloxone at mu opioid receptors. Moreover, its reported plasma half-life is up to eight hours, which is significantly longer than naloxone’s half-life of less than two hours. This longer duration potentially reduces the likelihood of renarcotization, which can occur when a victim has taken a long-acting opioid like fentanyl, which has a half-life of seven to eight hours². In December 2020, the CDC issued a Health Alert Network Advisory warning of substantial increases in drug overdose deaths across the U.S. driven primarily by increases in deaths involving synthetic opioids. Based on the potency of synthetic opioids, the CDC advised healthcare providers to counsel patients that multiple doses of naloxone may be needed for a single overdose event³. The leadership of the National Institute of Health (NIH) has highlighted the need for stronger, longer-acting formulations of antagonists to help prevent overdose deaths4. The development of OPNT003 is supported by grants from the National Institute on Drug Abuse, part of the National Institutes of Health, and the Biological Advance Research and Development Agency. About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.For more information visit: www.opiant.com. Forward-Looking StatementsThis press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 4, 2021, including under the caption titled "Risk Factors." These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. References Centers for Disease Control and Prevention. Provisional Drug Overdose Death Counts. March 8 , 2021. Retrieved from https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.Ahonen J, Olkkola, K, Hynynen M, et al. Comparison of alfentanil, fentanyl, and sufentanil for total intravenous anesthesia with Propofol in patients undergoing coronary artery bypass surgery. Brit J Anaesth 2000;85:533-540.Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic. Distributed via the CDC Health Alert Network, December 17, 2020, CDCHAN-00438Volkow, N., Collins, F. The Role of Science in Addressing the Opioid Crisis. N Engl J Med. 2017. 377:391-394 For Media and Investor Inquiries:Ben Atkins, Opiant(310) 598-5410batkins@opiant.com

  • Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose
    GlobeNewswire

    Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose

    SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of approximately $7.4 million from the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health (“NIH”), to support the development of OPNT003, nasal nalmefene, for the treatment of opioid overdose. The grant was awarded under award number 5U01DA046093-03. With the substantial increase in drug overdose deaths across the United States, primarily driven by rapid increases in overdose deaths involving synthetic opioids, including illicitly manufactured fentanyl1, NIH leadership has highlighted the need for stronger, longer-acting formulations of antagonists to help prevent overdose deaths2. “The award of the final tranche of NIDA’s grant validates the progress we are making to develop OPNT003 for submission to the FDA,” said Roger Crystal, M.D., President and CEO, Opiant Pharmaceuticals. “If approved, we believe OPNT003 can make a meaningful contribution to the NIH strategy identifying scientific solutions and novel pharmacotherapies to save lives from opioid overdose, particularly in the face of more powerful and potentially dangerous synthetic opioids, such as fentanyl.” The Company also announced that Dr. Crystal will participate in a panel presentation entitled, “Confronting the Opioid Crisis in the Age of Fentanyl and the Coronavirus Pandemic,” at the Rx Drug Abuse and Heroin Summit taking place virtually April 5-9, 2021. The panel will take place on April 6 from 2-3 p.m., EST. Further details are available at: https://www.eventscribe.com/2021/RxSummit2021/agenda.asp?startdate=4/6/2021&enddate=4/6/2021&BCFO=&pfp=Browse%20by%20Day&tn=&cpf2=&cus2=&pta= In addition to the grant from NIDA, the development of OPNT003 is supported by a contract with the Biological Advance Research and Development Agency. About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information, visit: www.opiant.com. Forward-Looking StatementsThis press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 4, 2021, including under the caption titled "Risk Factors." These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. References Centers for Disease Control and Prevention. Provisional Drug Overdose Death Counts. March 8 , 2021. Retrieved from https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.Volkow, N., Collins, F. The Role of Science in Addressing the Opioid Crisis. N Engl J Med. 2017. 377:391-394 For Media and Investor Inquiries:Ben Atkins, Opiant(310) 598-5410batkins@opiant.com

  • Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.
    GlobeNewswire

    Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.

    SANTA MONICA, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Lorianne Masuoka, M.D., to its Board of Directors, effective immediately. Dr. Masuoka will establish and chair a science and technology Board Committee. “We are delighted to welcome Dr. Masuoka to the Opiant Board of Directors,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “Dr. Masuoka’s extensive experience successfully expanding the depth and value of development pipelines of several biotech companies will be incredibly valuable to Opiant as we advance our mission to develop new medicines for the potential treatment of addictions and drug overdose.” “I am excited to join the board of directors at Opiant,” said Dr. Masuoka. “Opiant is working toward solving some of the greatest medical crises facing people worldwide, and has several promising programs with the potential to provide transformative treatments to patients suffering the affliction of addiction. I look forward to working alongside the Opiant team and leveraging my experience to develop and deliver on its pipeline.” Dr. Masuoka has more than 20 years of experience building and expanding high value pipelines in the biopharmaceutical industry that have resulted in drug approvals and strategic alliances. She is a board-certified neurologist who has successfully created and overseen high performing teams to lead the clinical development of new medicines, with a focus in neurology, oncology and pain. Dr. Masuoka served as chief medical officer of InVivo Therapeutics, Cubist Pharmaceuticals (now Merck), and Nektar Therapeutics where, as a member of executive management, she managed teams in the areas of clinical research, pharmacovigilance, biostatistics and data management, regulatory affairs, reimbursement and clinical operations. Previously, she held various roles of increasing responsibility at FivePrime Therapeutics (now Amgen) and Chiron (now Novartis). In addition to her executive roles, Dr. Masuoka most recently served as a Board member at Pfenex Inc (now Ligand). Dr. Masuoka received her medical degree from the University of California, Davis, where she also completed her residency in neurology. She completed her epilepsy fellowship at Yale University and is board certified by the American Board of Psychiatry and Neurology. About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.For more information visit: www.opiant.com. Forward-Looking StatementsThis press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 4, 2021, including under the caption titled "Risk Factors." These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. For Media and Investor Inquiries:Ben Atkins, Opiant(310) 598-5410batkins@opiant.com